Protalix BioTherapeutics Q3 2026 Results: Net Income $3.96M, Up 68.2% YoY
Protalix BioTherapeutics reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.1 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a substantial increase in total revenue to $75.6 million, primarily due to a surge in license and R&D services revenue.
- Key figure
- Net income $3.96M · +68.2% YoY